56 results about "Cysteine formation" patented technology

The invention provides a GLP-1 dimer, a preparation method therefore and an application thereof. The GLP-1 dimer is formed by two GLP-1 monomers containing cysteine connected via a disulfide bond formed by cysteine. The general formula of the GLP-1 monomer containing cysteine is 7HAEX10T FTSX15V SSYLE X22X23AAKEFIX30W LX33KGR G37; wherein X10 is aglycine or cysteine, X15 is aspartic acid or cysteine, X22 is glycine or cysteine, X23 is leucine or cysteine, X30 is alanine or cysteine, X33 is valine or cysteine, and only one among X10, X15, X22, X23, X30 and X33 is cysteine. The GLP-1 dimer in the invention has an in vivo half-life of more than 8 to 96 hours, thus greatly facilitating clinical promotion and application.

The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.

The invention discloses a staphylokinase mutant, wherein cysteine is introduced to the C-end of the staphylokinase mutant. Compared with the wild type staphylokinase, the C-end of the mutant has three more amino acids, namely glycine-glycine-cysteine (Gly-Gly-Cys). The invention also discloses a preparation method of the dimer of the staphylokinase mutant. The dimerization method of the staphylokinase is that the two maleimide groups of the homotype bifunctional binder 1,4-dimaleimide butane and the cysteine at the C-end of the staphylokinase are utilized to form a stable covalent bond. The invention also discloses a preparation method for realizing the N-end site-specific modificaton of polyethylene glycol by using the dimer of the staphylokinase mutant. Under special conditions, methoxypolyethylene glycol-propionaldehyde is connected with one N-end of the staphylokinase dimer molecule through the covalent bond. The biological activity of the polyethylene glycol modified product of the staphylokinase dimer is higher than that of the modified product of the staphylokinase monomer.

The invention provides the molecular degeneration of human growth hormone release hormone (HGHRH) peptides and its di clustering in the treatment of GH deficiency, infertility, dementia, diabetes, and enhanced immunity.The di agent of the present invention is two similar HGHRH -like peptide monomers that contain a single beurine molecular degeneration are connected by a sulfur (sulfurine formed by cysteine, and form an H -shaped structure (internal single ser → CYS inside the molecule → CYSreplace).The present invention also modifies the fatty acid chain of one of the lysine ε‑ amino groups of one of the lysine in the GHRH -like peptide.Extend the GHRH -like peptide monomer or di -polycatus in the body through fatty acid decoration, up to 17 days in the GH in the body.The present invention found that GHRH diodes with long -term activity have AIB → 2 ALA replacement, 18 C‑ 18 C formal sulfur formation, C20 fatty acid chain modification, and C -side amineization structure.

The present invention provides a glucagon-like peptide-2 analogue dimer, a preparation method and an application thereof, wherein two identical or different GLP-2 analogue monomers form a disulfide bond through cysteines on the monomers so as to prepare the dimer. The dimer preparation method comprises: adopting an Fmoc solid phase polypeptide synthesis method to synthesize a GLP-2 analogue monomer, and making the synthesized GLP-2 analogue monomers form a disulfide bond between the monomers. The application is an application of the GLP-2 analogue dimer in preparation of drugs for treatment of gastrointestinal related diseases. According to the present invention, with the GLP-2 analogue dimer formed from the GLP-2 analogue monomer, the problem of the short half-life of the GLP-2 is overcome, and the half-life of the GLP-2 analogue dimer can achieve more than 8-96 h in vivo, and is significantly prolonged compared with the half-life of the GLP-2 administered separately so as to substantially and easily achieve clinical promotion and application.